Citations (74)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Vishesh Patel & Juthaporn Cowan. (2020) Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency. Expert Review of Clinical Immunology 16:7, pages 711-716.
Read now
Read now
Mihai Ancau, Achim Berthele & Bernhard Hemmer. (2019) CD20 monoclonal antibodies for the treatment of multiple sclerosis:
up-to-date. Expert Opinion on Biological Therapy 19:8, pages 829-843.
Read now
Read now
Kleber Jordão de Souza, Rodrigo Sala Ferro, Luiz Euribel Prestes-Carneiro, Paula Andreia Martins Carrilho & Dewton de Moraes Vasconcelos. (2018) Infectious diseases and immunological markers associated with patients with non-Hodgkin lymphoma treated with rituximab. Immunopharmacology and Immunotoxicology 40:1, pages 13-17.
Read now
Read now
Articles from other publishers (71)
Johanne Liberatore, Yann Nguyen, Jérôme Hadjadj, Pascal Cohen, Luc Mouthon, Xavier Puéchal, Loïc Guillevin & Benjamin Terrier. (2024) Risk factors for hypogammaglobulinemia and association with relapse and severe infections in ANCA-associated vasculitis: A cohort study. Journal of Autoimmunity 142, pages 103130.
Crossref
Crossref
Claire Dossier, Stéphanie Bonneric, Véronique Baudouin, Thérésa Kwon, Benjamin Prim, Alexandra Cambier, Anne Couderc, Christelle Moreau, Georges Deschenes & Julien Hogan. (2023) Obinutuzumab in Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome in Children. Clinical Journal of the American Society of Nephrology 18:12, pages 1555-1562.
Crossref
Crossref
Rocío Díaz Acedo, Silvia Artacho Criado, Eduardo Ríos Herranz, Antonio Gutiérrez Pizarraya, Irene Sánchez Romero & Esther Márquez Saavedra. (2023) Hypogammaglobulinemia after front-line immunochemotherapy in patients with follicular lymphoma. Journal of Oncology Pharmacy Practice 29:8, pages 1982-1989.
Crossref
Crossref
Jantien W. Wieringa, Mirjam J. Esser, Jan G.M.C. Damoiseaux, Gertjan A. Driessen & Joyce J.B.C. van Beers. (2023) B cell depletion in infants after intra uterine exposure to immunomodulating chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP): A case series and review of the literature. Clinical Immunology Communications 4, pages 1-6.
Crossref
Crossref
Moustafa S. Alhamadh, Thamer S. Alhowaish, Alaa Mathkour, Bayan Altamimi, Shahd Alheijani & Abdulrahman Alrashid. (2023) Infection Risk, Mortality, and Hypogammaglobulinemia Prevalence and Associated Factors in Adults Treated with Rituximab: A Tertiary Care Center Experience. Clinics and Practice 13:6, pages 1286-1302.
Crossref
Crossref
Aleksandra Zurowska, Magdalena Drozynska-Duklas, Rezan Topaloglu, Antonia Bouts, Olivia Boyer, Mohan Shenoy, Marina Vivarelli, H. Alpay, R. Andersen, G. Ariceta, B. Atmış, U. S. Bayrakçı, B. Esrea, V. Baudouin, N. Bervina, E. Benetti, E. Berard, A. Bjerre, M. Christian, A. Couderc, J. Dehoorne, G. Deschenes, C. Dossier, R. Düşünsel, Z. Ekinci, F. Emma, L. Espinoza, A. Gianviti, M. Herrero Goñi, G. Guido, L. Ghio, J. Groothoff, D. Ö. Hacıhamdioğlu, M. Espino Hernández, A. Jankauskiene, M. Kagan, M. Kemper, M. Kovacevic, S. Kohl, R. T. Kramar, M. López-González, A. M. Aris, S. Maringhini, M. Marlais, M. Melgosa, A. Mitsioni, G. Montini, A. Moczulska, L. Murer, V. Obukhova, J. Oh, P. Ortega, Z. B. Özçakar, T. Ulinski, A. Pasini, T. Papalia, S. Paunova, A. Pena, C. Pecoraro, E. Petrosyan, L. Peruzzi, N. Printza, L. Prikhodina, C. Pietrement, S. Rittig, D. Rodrigo, N. Savenkova, M. Saraga, F. L. Sever, M. Schreuder, M. Szczepanska, V. Tasic, B. Tonshoff, K. Tullus, J. Vara, J. Vande Walle, E. Volokhina, J. Zieg, A. Waters, L. T. Weber, N. Webbe, M. Wasiak, K. Endén, A. Tsygin, R. Grenda, A. Raes, J. M. Van Hoeck Koen, B. Adams, M. Aksenova, B. Ranchin, N. Hooman, I. Ogarek, T. Seeman, M. Fila, L. Oni, S. Mir, R. Novo, S. Stabouli, J. Vara-Martín, J. A. E. van Wijk, R. Ehren, Z. Bekassy, M. Herthelius, F. Becherucci, H. Shasha-Lavsky, F. Santos, M. Feldkötter, M. Pańczyk-Tomaszewska, J. Harambat, D. Grima, I. Gökçe, A. Teixeira, C. Licht, I. M. Schmidt, P. Brandström & N. Dinçel. (2023) Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey. Pediatric Nephrology 38:9, pages 3035-3042.
Crossref
Crossref
Chamaida Plasencia-Rodríguez, Ana Martínez-Feito, Marta Hernández, Lucia Del Pino-Molina, Marta Novella-Navarro, Yolanda Serrano, Miguel González-Muñoz, Diana Peiteado, Gema Bonilla, Irene Monjo, Laura Nuño, Carolina Tornero, Eduardo López-Granados, Alejandro Balsa & Pilar Nozal. (2023) Immune response after SARS-CoV-2 vaccination in patients with inflammatory immune-mediated diseases receiving immunosuppressive treatment. Allergy, Asthma & Clinical Immunology 19:1.
Crossref
Crossref
Xavier Boumaza, Margaux Lafaurie, Emmanuel Treiner, Ondine Walter, Gregory Pugnet, Guillaume Martin-Blondel, Damien Biotti, Jonathan Ciron, Arnaud Constantin, Marie Tauber, Florent Puisset, Guillaume Moulis, Laurent Alric, Yves Renaudineau, Dominique Chauveau & Laurent Sailler. (2023) Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases. International Immunopharmacology 120, pages 110342.
Crossref
Crossref
Giuliana Giardino, Roberta Romano, Vassilios Lougaris, Riccardo Castagnoli, Francesca Cillo, Lucia Leonardi, Francesco La Torre, Annarosa Soresina, Silvia Federici, Caterina Cancrini, Lucia Pacillo, Elisabetta Toriello, Bianca Laura Cinicola, Stefania Corrente, Stefano Volpi, Gian Luigi Marseglia, Claudio Pignata & Fabio Cardinale. (2023) Immune tolerance breakdown in inborn errors of immunity: Paving the way to novel therapeutic approaches. Clinical Immunology 251, pages 109302.
Crossref
Crossref
Laura Cannon, Alice Pan, Leonard Kovalick, Aliese Sarkissian & Eveline Y. Wu. (2023) Secondary immunodeficiencies and infectious considerations of biologic immunomodulatory therapies. Annals of Allergy, Asthma & Immunology 130:6, pages 718-726.
Crossref
Crossref
Tejas S. Athni & Sara Barmettler. (2023) Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab. Annals of Allergy, Asthma & Immunology 130:6, pages 699-712.
Crossref
Crossref
Eva Hlavackova, Zdenka Krenova, Arpad Kerekes, Peter Slanina & Marcela Vlkova. (2023) B cell subsets reconstitution and immunoglobulin levels in children and adolescents with B non-Hodgkin lymphoma after treatment with single anti CD20 agent dose included in chemotherapeutic protocols: single center experience and review of the literature. Biomedical Papers.
Crossref
Crossref
Berkan Armağan, Hatice Ecem Konak, Bahar Özdemir, Hakan Apaydın, Ebru Atalar, Pınar Akyüz Dağlı, Serdar Can Güven, Abdulsamet Erden, Orhan Küçükşahin, Ahmet Omma & Şükran Erten. (2023)
COVID
‐19 disease frequency, risk factors, and re‐infection rates in patients with autoimmune rheumatic disease receiving rituximab
. International Journal of Rheumatic Diseases 26:5, pages 930-937.
Crossref
Crossref
Alira Fraga Olvera, Miguel Angel Saavedra-Salinas, Jesus Quetzalcoatl Beltrán Mendoza & Elizabeth Mendieta Flores. (2023) Prevalencia de hipogammaglobulinemia persistente en pacientes con enfermedad autoinmune que reciben rituximab en un centro de referencia nacional en México. Revista Alergia México 69:4, pages 171-182.
Crossref
Crossref
Yuta Inoki, Kentaro Nishi, Mai Sato, Masao Ogura & Koichi Kamei. (2022) The association between hypogammaglobulinemia severity and infection risk in rituximab-treated patients with childhood-onset idiopathic nephrotic syndrome. Pediatric Nephrology 38:2, pages 451-460.
Crossref
Crossref
Nina Shah, S. Shahzad Mustafa & Donald C. Vinh. (2023) Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology. Critical Reviews in Oncology/Hematology 181, pages 103896.
Crossref
Crossref
Annaliesse Blincoe, Roxane Labrosse & Roshini S. Abraham. (2022) Acquired B-cell deficiency secondary to B-cell-depleting therapies. Journal of Immunological Methods 511, pages 113385.
Crossref
Crossref
S. Shahzad Mustafa, Nicholas L. Rider & Stephen Jolles. (2022) Immunosuppression in Patients With Primary Immunodeficiency—Walking the Line. The Journal of Allergy and Clinical Immunology: In Practice 10:12, pages 3088-3096.
Crossref
Crossref
Georgie Mathew, Aditi Sinha, Aijaz Ahmed, Neetu Grewal, Priyanka Khandelwal, Pankaj Hari & Arvind Bagga. (2022) Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial. Pediatric Nephrology 37:12, pages 3117-3126.
Crossref
Crossref
Giorgio Ottaviano, Mayla Sgrulletti & Viviana Moschese. (2022) Secondary rituximab‐associated versus primary immunodeficiencies: The enigmatic border. European Journal of Immunology 52:10, pages 1572-1580.
Crossref
Crossref
Iris M. Otani, Heather K. Lehman, Artemio M. Jongco, Lulu R. Tsao, Antoine E. Azar, Teresa K. Tarrant, Elissa Engel, Jolan E. Walter, Tho Q. Truong, David A. Khan, Mark Ballow, Charlotte Cunningham-Rundles, Huifang Lu, Mildred Kwan & Sara Barmettler. (2022) Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees. Journal of Allergy and Clinical Immunology 149:5, pages 1525-1560.
Crossref
Crossref
Yuta Inoki, Koichi Kamei, Kentaro Nishi, Mai Sato, Masao Ogura & Akira Ishiguro. (2021) Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome. Pediatric Nephrology 37:5, pages 1057-1066.
Crossref
Crossref
Lili Yao, Yu Huang & Andi Xu. (2022) Prognostic factors of severe pneumonia in patients treated with rituximab in the intensive care unit. Journal of International Medical Research 50:3, pages 030006052110632.
Crossref
Crossref
B. Guillet, A. Aouba, J.-Y. Borg, J.F. Schved & H. Lévesque. (2022) Characterizing hospital pathways for the care of acquired hemophilia in France using comprehensive national health data. La Revue de Médecine Interne 43:3, pages 139-144.
Crossref
Crossref
Chenjia He, Wenyu Li, Qibing Xie & Geng Yin. (2022) Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review. Frontiers in Immunology 12.
Crossref
Crossref
Nicholas Lafferty, Tushar Sehgal, Andrew Duncombe, Haider Katifi, David Allen & Shoura Karar. (2022) Favorable response to cyclophosphamide in a patient with refractory Guillain–Barre syndrome associated with chronic lymphocytic leukemia. International Journal of Case Reports and Images 13, pages 1.
Crossref
Crossref
Ide Smets & Gavin Giovannoni. (2022) Derisking CD20-therapies for long-term use. Multiple Sclerosis and Related Disorders 57, pages 103418.
Crossref
Crossref
Giuliana Giardino, Emilia Cirillo, Rosaria Prencipe, Roberta Romano, Francesca Cillo, Elisabetta Toriello, Veronica De Rosa & Claudio Pignata. 2022. Translational Autoimmunity. Translational Autoimmunity
73
95
.
Fanny Luterbacher, Fanette Bernard, Frédéric Baleydier, Emmanuelle Ranza, Peter Jandus & Geraldine Blanchard-Rohner. (2021) Case Report: Persistent Hypogammaglobulinemia More Than 10 Years After Rituximab Given Post-HSCT. Frontiers in Immunology 12.
Crossref
Crossref
Piero Ruscitti, Alessandro Conforti, Paola Cipriani, Roberto Giacomelli, Marco Tasso, Luisa Costa & Francesco Caso. (2021) Pathogenic implications, incidence, and outcomes of COVID-19 in autoimmune inflammatory joint diseases and autoinflammatory disorders. Advances in Rheumatology 61:1.
Crossref
Crossref
Merlin Wennmann, Simone Kathemann, Kristina Kampmann, Sinja Ohlsson, Anja Büscher, Dirk Holzinger, Adela Della Marina & Elke Lainka. (2021) A Retrospective Analysis of Rituximab Treatment for B Cell Depletion in Different Pediatric Indications. Frontiers in Pediatrics 9.
Crossref
Crossref
Nabil Seery, Sifat Sharmin, Vivien Li, Ai-Lan Nguyen, Claire Meaton, Roberts Atvars, Nicola Taylor, Kelsey Tunnell, John Carey, Mark P. Marriott, Katherine A. Buzzard, Izanne Roos, Chris Dwyer, Josephine Baker, Lisa Taylor, Kymble Spriggs, Trevor J. Kilpatrick, Tomas Kalincik & Mastura Monif. (2021) Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study. CNS Drugs 35:8, pages 907-918.
Crossref
Crossref
Stefanie D. Wade & Vasileios C. Kyttaris. (2021) Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study. Rheumatology International 41:6, pages 1115-1124.
Crossref
Crossref
Gerasimos Evangelatos, George E Fragoulis, Kalliopi Klavdianou, Melina Moschopoulou, Dimitrios Vassilopoulos & Alexios Iliopoulos. (2021) Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience. Rheumatology 60:5, pages 2375-2382.
Crossref
Crossref
Stephen Jolles, Mauricette Michallet, Carlo Agostini, Michael H. Albert, David Edgar, Roberto Ria, Livio Trentin & Vincent Lévy. (2021) Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus. European Journal of Haematology 106:4, pages 439-449.
Crossref
Crossref
Effrossyni Gkrania-Klotsas & Dinakantha S Kumararatne. (2021) Serious Infectious Complications After Rituximab Therapy in Patients With Autoimmunity: Is This the Final Word?. Clinical Infectious Diseases 72:5, pages 738-742.
Crossref
Crossref
Sarah Stabler, Jonathan Giovannelli, David Launay, Angélique Cotteau-Leroy, Marion Heusele, Guillaume Lefèvre, Louis Terriou, Marc Lambert, Sylvain Dubucquoi, Eric Hachulla & Vincent Sobanski. (2021) Serious Infectious Events and Immunoglobulin Replacement Therapy in Patients With Autoimmune Disease Receiving Rituximab: A Retrospective Cohort Study. Clinical Infectious Diseases 72:5, pages 727-737.
Crossref
Crossref
M. Isabel Leite. (2021) Reader Response: Evaluation of Efficacy and Tolerability of First-Line Therapies in NMOSD. Neurology 96:6, pages 294-295.
Crossref
Crossref
Sarah Healy, Kariem Tarik Elhadd, Emily Gibbons, Dan Whittam, Michael Griffiths, Anu Jacob & Saif Huda. (2021) Treatment of myelin oligodendrocyte glycoprotein immunoglobulin G–associated disease. Clinical and Experimental Neuroimmunology 12:1, pages 22-41.
Crossref
Crossref
Casey Lee McAtee, Joseph Lubega, Kristen Underbrink, Kristen Curry, Pavlos Msaouel, Martha Barrow, Eyal Muscal, Timothy Lotze, Poyyapakkam Srivaths, Lisa R. Forbes, Carl Allen & M. Brooke Bernhardt. (2021) Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults. JAMA Network Open 4:2, pages e2036321.
Crossref
Crossref
Anji Xiong, Guancui Yang, Zhuoyao Song, Chen Xiong, Deng Liu, Yu Shuai, Linqian He, Liangwen Zhang, Zepeng Guo & Shiquan Shuai. (2021) Rituximab in the treatment of immune-mediated necrotizing myopathy: a review of case reports and case series. Therapeutic Advances in Neurological Disorders 14, pages 175628642199891.
Crossref
Crossref
S. Shahzad Mustafa. 2021. Primary and Secondary Immunodeficiency. Primary and Secondary Immunodeficiency
363
380
.
Georges Jalkh, Rachelle Abi Nahed, Gabrielle Macaron & Mary Rensel. (2020) Safety of Newer Disease Modifying Therapies in Multiple Sclerosis. Vaccines 9:1, pages 12.
Crossref
Crossref
Takeo Fujino, Yuto Kumai, Daisuke Nitta, Luise Holzhauser, Ann Nguyen, Laura Lourenco, Daniel Rodgers, Jayant Raikhelkar, Gene Kim, Gabriel Sayer & Nir Uriel. (2020) Hypogammaglobulinemia following heart transplantation: Prevalence, predictors, and clinical importance. Clinical Transplantation 34:12.
Crossref
Crossref
Julián E. Barahona-Correa, Alejandro De la Hoz, María José López, Javier Garzón, Yannick Allanore & Gerardo Quintana-López. (2020) Infecciones y esclerosis sistémica: un desafío emergente. Revista Colombiana de Reumatología 27, pages 62-84.
Crossref
Crossref
S. Shahzad Mustafa, Saad Jamshed, Karthik Vadamalai & Allison Ramsey. (2020) The Use of 20% Subcutaneous Immunoglobulin Replacement Therapy in Patients With B Cell Non-Hodgkin Lymphoma With Humoral Immune Dysfunction After Treatment With Rituximab. Clinical Lymphoma Myeloma and Leukemia 20:9, pages e590-e596.
Crossref
Crossref
Brandi L. Vollmer, Kavita Nair, Stefan Sillau, John R. Corboy, Timothy Vollmer & Enrique Alvarez. (2020) Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology 7:9, pages 1466-1476.
Crossref
Crossref
Victoria Prockl, Florian T. Nickel, Kathrin S. Utz, Kilian Fröhlich, Tobias Engelhorn, Max-Josef Hilz, De-Hyung Lee, Ralf A. Linker & Konstantin Huhn. (2020) Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients. Journal of the Neurological Sciences 415, pages 116973.
Crossref
Crossref
Jonas Graf, Philipp Albrecht, Norbert Goebels, Orhan Aktas & Hans-Peter Hartung. (2020) Ocrelizumab zur Behandlung der Multiplen SkleroseOcrelizumab for treatment of multiple sclerosis. Der Nervenarzt 91:8, pages 722-734.
Crossref
Crossref
Lali G. Babicheva & Irina V. Poddubnaya. (2020) Accompanying therapy in oncohematological patients with secondary immunodeficiency. Journal of Modern Oncology 22:2, pages 89-97.
Crossref
Crossref
Angela Deyà-MartínezYadira Gordón, Cristina Molina-AnguitaAlexandru VlageaMonica PiquerManel Juan, Ana Esteve-SoléJordi AntónÁlvaro Madrid, Ana García-GarcíaAna M. PlazaThaís ArmangueLaia Alsina. (2020) Single-cycle rituximab-induced immunologic changes in children. Neurology Neuroimmunology & Neuroinflammation 7:4.
Crossref
Crossref
Julián E. Barahona-Correa, Alejandro De la Hoz, María José López, Javier Garzón, Yannick Allanore & Gerardo Quintana-López. (2020) Infections and systemic sclerosis: an emerging challenge. Revista Colombiana de Reumatología (English Edition) 27, pages 62-84.
Crossref
Crossref
Khalaf Kridin & A. Razzaque Ahmed. (2020) Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia. Autoimmunity Reviews 19:3, pages 102466.
Crossref
Crossref
Cyrielle Parmentier, Jean-Daniel Delbet, Stéphane Decramer, Olivia Boyer, Julien Hogan & Tim Ulinski. (2019) Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome. Pediatric Nephrology 35:3, pages 455-462.
Crossref
Crossref
Iris Najjar, Florina Paluca, Konstantinos Loukidis & Philip E. Tarr. (2020) Recurrent Campylobacter Enteritis in Patients with Hypogammaglobulinemia: Review of the Literature. Journal of Clinical Medicine 9:2, pages 553.
Crossref
Crossref
Sigrun Einarsdottir, Per Ljungman, Bertil Kaijser, Malin Nicklasson, Peter Horal, Helen Norder, Tomas Bergström & Mats Brune. (2020) Humoral immunity to tetanus, diphtheria and polio in adults after treatment for hematological malignancies. Vaccine 38:5, pages 1084-1088.
Crossref
Crossref
Joshua A. HillElizabeth M. KrantzKevin A. Hay, Sayan DasguptaTerry Stevens-AyersRachel A. Bender Ignacio, Merav BarJoyce MaaloufSindhu Cherian, Xueyan Chen, Greg Pepper, Stanley R. RiddellDavid G. MaloneyMichael J. BoeckhCameron J. Turtle. (2019) Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. Blood Advances 3:22, pages 3590-3601.
Crossref
Crossref
Renaud Prevel, Claire Roubaud-Roubaud, Samuel Gourlain, Matthieu Jamme, Karine Peres, Ygal Benhamou, Lionel Galicier, Elie Azoulay, Pascale Poullin, François Provôt, Eric Maury, Claire Presne, Mohamed Hamidou, Samir Saheb, Alain Wynckel, Aude Servais, Stéphane Girault, Yahsou Delmas, Valérie Chatelet, Jean-François AugustoSrSr, Christiane Mousson, Pierre Perez, Jean-Michel Halimi, Tarik Kanouni, Alexandre Lautrette, Anne Charvet Rumpler, Christophe Deligny, Dominique Chauveau, Agnès VeyradierPrPr & Paul Coppo. (2019) Prognostic and Long-term Survival of Immune Thrombotic Thrombocytopenic Purpura in older patients. Blood.
Crossref
Crossref
Babak Soleimani, Katy Murray & David Hunt. (2019) Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis. Drug Safety 42:8, pages 941-956.
Crossref
Crossref
Ana Catarina Duarte, Ana Cordeiro, Bruno Miguel Fernandes, Miguel Bernardes, Patrícia Martins, Inês Cordeiro, Tânia Santiago, Maria Inês Seixas, Ana Roxo Ribeiro & Maria José Santos. (2019) Rituximab in connective tissue disease–associated interstitial lung disease. Clinical Rheumatology 38:7, pages 2001-2009.
Crossref
Crossref
Arun Venkatesan. (2019) Immune-mediated encephalitis for the infectious disease specialist. Current Opinion in Infectious Diseases 32:3, pages 251-258.
Crossref
Crossref
Natacha Zlocowski, Veronica Grupe, Yohana C. Garay, Gustavo A. Nores, Ricardo D. Lardone & Fernando J. Irazoqui. (2019) Purified human anti-Tn and anti-T antibodies specifically recognize carcinoma tissues. Scientific Reports 9:1.
Crossref
Crossref
Pierluigi Marzuillo, Stefano Guarino, Tiziana Esposito, Anna Di Sessa, Sara Immacolata Orsini, Daniela Capalbo, Emanuele Miraglia del Giudice & Angela La Manna. (2019) Rituximab-induced IgG hypogammaglobulinemia in children with nephrotic syndrome and normal pre-treatment IgG values. World Journal of Clinical Cases 7:9, pages 1021-1027.
Crossref
Crossref
Dalia Rotstein & Xavier Montalban. (2019) Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nature Reviews Neurology 15:5, pages 287-300.
Crossref
Crossref
Smita Y. Patel, Javier Carbone & Stephen Jolles. (2019) The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management. Frontiers in Immunology 10.
Crossref
Crossref
Mark Ponsford, Daniel Castle, Tayyeb Tahir, Rebecca Robinson, Wendy Wade, Rachael Steven, Kathryn Bramhall, Mo Moody, Emily Carne, Catherine Ford, Daniel Farewell, Paul Williams, Tariq El-Shanawany & Stephen Jolles. (2018) Clozapine is associated with secondary antibody deficiency. The British Journal of Psychiatry 214:2, pages 83-89.
Crossref
Crossref
Greta Zoehner, Andrei Miclea, Anke Salmen, Nicole Kamber, Lara Diem, Christoph Friedli, Maud Bagnoud, Farhad Ahmadi, Myriam Briner, Nazanin Sédille-Mostafaie, Constantinos Kilidireas, Leonidas Stefanis, Andrew Chan, Robert Hoepner & Maria Eleftheria Evangelopoulos. (2019) Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course. Therapeutic Advances in Neurological Disorders 12, pages 175628641987834.
Crossref
Crossref
Emma C. Tallantyre, Neil P. Robertson & Stephen Jolles. (2018) Secondary antibody deficiency in neurology. Current Opinion in Allergy & Clinical Immunology 18:6, pages 481-488.
Crossref
Crossref
K. Pape, F. Zipp & S. Bittner. (2018) Neues aus der Immuntherapie bei Multipler SkleroseNew aspects of immunotherapy in multiple sclerosis. Der Nervenarzt 89:12, pages 1365-1370.
Crossref
Crossref
Sara Barmettler, Mei-Sing Ong, Jocelyn R. Farmer, Hyon Choi & Jolan Walter. (2018) Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia. JAMA Network Open 1:7, pages e184169.
Crossref
Crossref
E. C. Tallantyre, D. H. Whittam, S. Jolles, D. Paling, C. Constantinesecu, N. P. Robertson & A. Jacob. (2018) Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. Journal of Neurology 265:5, pages 1115-1122.
Crossref
Crossref